Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis.
It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth.
Pregnancy category AU: B1
Routes of administration-By mouth
Protein binding 82–90%
Metabolism- Liver (primarily CYP1A2)
Elimination half-life 10 hours
Excretion- Feces, urine
Deucravacitinib is indicated for the treatment of adults with moderate-to-severe plaque psoriasis.
It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).